MWMichael Wilke

Michael Wilke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael Wilke has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Progression of Heart Failure in People with Type 2 Diabetes in Germany: An Analysis Using German Health Insurance Claims Data

    by Keni Cheng-Siang Lee, Tobias Wagner, Adee Kennedy, Michael Wilke

    Background: Individuals with type 2 diabetes (T2D) show high risk of heart failure (HF). Left ventricular ejection fraction is a major factor for disease progression. In Germany, no recent longitudinal data are available. Objectives: To (1) measure the proportion of individuals with T2D who acquire HF over 2 years and (2) categorize ejection fraction using routine data and an algorithm, and (3) understand progression of HF in 5-year follow-up. Methods: This descriptive, retrospective study used longitudinal data from German statutory health insurance claims. A model using coded data classified the patients with HF into ejection fraction (EF) categories. Individuals were selected during 2013, with an inclusion period from 2014 to 2015 and a follow-up from 2016 to 2020. Baseline characteristics included demographic data, disease stage, comorbidities, and risk factors. Follow-up criteria included major adverse cardiac events (MACEs), EF category, and mortality. Disease progression was visualized by Sankey plots. Results: Among the 173 195 individuals with T2D identified in 2013, 6725 (median age, 74 years) developed HF in 2014 or 2015. 34.4% of individuals had MACEs, and 42.9% died over 5 years. Myocardial infarction (42%) was the most common event, followed by stroke (32%) and hospitalization (28%). A total of 5282 (78.54%) patients were classified into preserved EF and 1443 (21.46%) into reduced EF. Survival after 5 years was 71% in HF for preserved EF patients, and 29% in the HF for those with reduced EF. Conclusion: Heart failure is relevant in individuals with diabetes. A high number of patients may likely not survive a 5-year period. Validation of the model with German data is highly desirable. New ways of close monitoring could help improve outcomes.

  • Open Access

    Clinical and economic burden of surgical site infections in inpatient care in Germany: A retrospective, cross-sectional analysis from 79 hospitals

    by Christian Eckmann, Axel Kramer, Ojan Assadian, Steffen Flessa, Claudia Huebner, Kristian Michnacs, Christian Muehlendyck, Kim Mirjam Podolski, Michael Wilke, Wolfgang Heinlein, et al.

    Background: Surgical site infections (SSI) present a substantial burden to patients and healthcare systems. This study aimed to elucidate the prevalence of SSIs in German hospitals and to quantify their clinical and economic burden based on German hospital reimbursement data (G-DRG). Methods: This retrospective, cross-sectional study used a 2010–2016 G-DRG dataset to determine the prevalence of SSIs in hospital, using ICD-10-GM codes, after surgical procedures. The captured economic and clinical outcomes were used to quantify and compare resource use, reimbursement and clinical parameters for patients who had or did not have an SSI. Findings: Of the 4,830,083 patients from 79 hospitals, 221,113 were eligible. The overall SSI prevalence for the study period was 4.9%. After propensity-score matching, procedure type, immunosuppression and BMI ≥30 were found to significantly affect the risk of SSI (p<0.001). Mortality and length of stay (LOS) were significantly higher in patients who had an SSI (mortality: 9.3% compared with 4.5% [p<0.001]; LOS (median [interquartile range, IQR]): 28 [27] days compared with 12 [8] days [p<0.001]). Case costs were significantly higher for the SSI group (median [IQR]) €19,008 [25,162] compared with € 9,040 [7,376] [p<0.001]). A median underfunding of SSI was identified at €1,534 per patient. Interpretation: The dataset offers robust information about the “real-world” clinical and economic burden of SSI in hospitals in Germany. The significantly increased mortality of patients with SSI, and their underfunding, calls for a maximization of efforts to prevent SSI through the use of evidence-based SSI-reduction care bundles.


  • Open Access

    Tackling Extended Hospital Stays in Patients with Acute Bacterial Skin and Skin Structure Infections

    by Gavin Barlow, Michael Wilke, Guillaume Béraud

    Hospitalisation rates for acute bacterial skin and skin structure infection (ABSSSI) are rising and represent a large pharmacoeconomic burden as treatment may involve an extended number of days of antibiotic therapy. This article first aims to provide a review of treatment challenges associated with ABSSSIs in both hospital and outpatient settings, and shows that while more traditionally treatment has been conducted in a hospital setting, for a number of patients, a variety of considerations, including pharmacoeconomics, infection control, and patient preference, has led to the development of recommendations to assess the eligibility of patients for early discharge from hospital to complete their antibiotic regimen in the outpatient setting. However, such patients require monitoring for drug adherence to oral regimens or complications associated with daily intravenous administration, such as injection site reactions and infection. This review also focuses on one of a number of new antibiotics for ABSSSI, dalbavancin, as the long-acting glycopeptide with the most clinical experience to date. This antibiotic has been shown to be as effective as a daily/twice daily regimen with similar safety profiles. Health economic analysis of dalbavancin is also presented. It has shown that in some, though not all, clinical settings a reduction in the overall treatment cost is evident as, despite a higher medication cost, the lower hospitalisation time can lead to greater cost savings. In conclusion, while the burden of ABSSSI is rising, new treatment options provide additional therapeutic choice, although pharmacoeconomic considerations might limit use in some cases.

  • Open Access

    Carbapenem-resistant gram-negative bacteria in Germany: incidence and distribution among specific infections and mortality: an epidemiological analysis using real-world data

    by Michael H. Wilke, Birgit Preisendörfer, Anna Seiffert, Maria Kleppisch, Caroline Schweizer, Stephan Rauchensteiner

    Purpose: Infections with carbapenem-resistant gram-negative bacteria (in Germany classified as 4MRGN) are a growing threat in clinical care. This study was undertaken to understand the overall burden of 4MRGN infections in Germany in the context of a Health Technology Appraisal (HTA) for Ceftazidime/Avibactam (CAZ/AVI). Besides, the incidences mortality was an endpoint of interest. Methods: To assess infections with carbapenem-resistant gram-negative bacteria and related mortality, three different data sources have been used. From the German statistics office (DESTATIS) data have been retrieved to obtain the overall frequency these pathogens. Via two other databases, the German analysis database (DADB) and a Benchmarking of > 200 hospitals in a representative sample (BM-DB), the distribution of the infections and the mortality have been analyzed. Results: DESTATIS data showed a total of 11,863 carbapenem-resistant gram-negative bacteria codings, of which 10,348 represent infections and 1515 carriers. The most frequent infections were complicated urinary tract infections (cUTI) (n = 2,337), followed by pneumonia (n = 1006) and intra-abdominal infections (n = 730). A considerable amount of patients had multiple infections in one hospital episode (n = 1258). In-hospital mortality was 18.6% in DADB and 14.3% in the BM-DB population, respectively. In cases with additional bloodstream infections, DADB mortality was correspondingly higher at 33.0%. DADB data showed an incremental mortality increase of 5.7% after 30 days and 10.0% after 90 days resulting in a cumulative 90 day mortality of 34.3%. Conclusions: Infections with carbapenem-resistant gram-negative bacteria are still rare (6.8–12.4 per 100,000) but show a significant increase in mortality compared to infections with more sensitive pathogens. Using different data sources allowed obtaining a realistic picture.


    • 15 December 2020
      • Vol. 8
    Open Access

    Clinical and economical improvements after introducing rapid identification of bacteria and early antibiotic susceptibility testing in sepsis and bloodstream infections. Results of the PHENOMENON study

    by Michael Wilke, Wolfgang Heinlein, Luis Stiefenhofer, Klaus-Friedrich Bodmann

    Background: Sepsis and bloodstream infections pose severe challenges in intensive care. Early reliable diagnosis is the key to successful therapy. The objective of the study presented here was to investigate the clinical and economical effects of the new PhenoTM BC test, which allows bacteria identification (ID) and antimicrobial susceptibility testing (AST) in approximately 7 hours after a blood culture becomes positive (BC+).


  • Frühe Optimierung der Antibiotikatherapie durch den schnellen Nachweis von Erregern und Empfindlichkeit

    by Michael Wilke, Kerstin Worf, Wolfgang Heinlein, Tilman Kast, Klaus-Friedrich Bodmann

  • Frühe Optimierung der Antibiotikatherapie durch den schnellen Nachweis von Erregern und Empfindlichkeit

    by M. Wilke, K. Worf, W. Heinlein, T. Kast, K.-F. Bodmann

    Zusammenfassung Einführung Schwere Infektionen erfordern frühe Optimierung der Antibiotikatherapie. Seit 2016 ermöglicht eine neue Methode Erregerdifferenzierung und Resistenztestung positiver Blutkulturen in weniger als 8 h. Ziel dieser Arbeit war, die ökonomischen Effekte der schnelleren Verfügbarkeit auf nationaler Ebene zu untersuchen und in einem Krankenhaus zu validieren. Material und Methoden In einer Literaturrecherche wurden der klinische und ökonomische Nutzen adäquater Therapie sowie die Rate der initial inadäquaten antibiotischen Therapie (IIAT) in der Indikation „Sepsis und Blutstrominfektionen“ ermittelt. Die Mittelwerte der gepoolten Studien wurden mit den Fallzahlen in Deutschland (Datenjahr 2015) für alle Fälle, in denen Sepsispatienten mit codiertem Keim und Intensivaufenthalt zu finden waren, in ein ökonomisches Modell integriert, das anschließend in einem Krankenhaus überprüft wurde. Ergebnisse Die Analyse von 14 Studien mit 6408 Patienten ergab eine mittlere Rate von 27,3 % IIAT. Aus 8 Studien (n = 2988) wurde eine durchschnittliche Verweildauer(VWD)-Einsparung von 4,7 Tagen bei adäquater Initialtherapie im Vergleich zu einer IIAT ermittelt. Mit einer VWD-Reduktion von 3,7 Tagen ließen sich im theoretischen Modell pro Fall im Mittel 1539 € einsparen. Eine konservative Variante mit einer IIAT von 20 % und VWD-Einsparungen von 2,5 Tagen ergab noch immer eine durchschnittliche Einsparung von 201 € pro Fall. Von 146 Fällen in der Validierung hatten 68 % eine positive Blutkultur. In 61 % der geprüften Fälle wäre eine Anpassung der Therapie erforderlich gewesen (35 % IIAT, 26 % Deeskalation). Nach Abzug der Kosten für den Test bei 60 Patienten ergaben sich mögliche Einsparungen von insgesamt 122.112 €; pro Fall über 2000 €. Zusammenfassung Sowohl die Ergebnisse des ökonomischen Modells als auch die Auswertung in einem Krankenhaus zeigen, dass eine schnelle adäquate Antibiotikatherapie ökonomisch günstig ist. Die Optimierung der antibiotischen Therapie durch einen frühzeitigen Nachweis des Erregers sowie der Empfindlichkeit mittels MHK stellt eine Möglichkeit dar, trotz hoher Kosten für die Diagnostik in der Klinik Einsparungen zu erzielen. Potenziale sollten krankenhausindividuell mittels systematischer Fallreviews ermittelt werden.


    • 23 October 2019
      • Vol. 7, Doc03

    Potential savings through single-dose intravenous Dalbavancin in long-term MRSA infection treatment - a health economic analysis using German DRG data.

    by Michael Wilke, Kerstin Worf, Birgit Preisendörfer, Wolfgang Heinlein, Tilman Kast, Klaus-Friedrich Bodmann

    Complicated infections such as osteomyelitis, skin and soft tissue infections or endocarditis often require antibiotic therapies that can last up to several weeks. The prolonged hospital length of stay (LOS) leads to a dramatic increase in costs. Single-dose intravenous Dalbavancin is a novel antimicrobial agent for the treatment of acute bacterial skin, skin structure and soft tissue infections (ABSSSI) that allows an earlier discharge of patients, resulting in potential savings. Joint, bone and prostheses infections (JBPI) are also related with long LOS. The aim of this study is to determine the economic effects of single-dose intravenous Dalbavancin in suitable patients with Methicillin-resistant Staphylococcus aureus infections in Germany. For this purpose, an analysis with real-world patient treatment data was performed, which was subsequently validated in a large German hospital. In total, ABSSSI patients with MRSA infections could stay 6.45 days shorter and 2,865 € could be saved while JBPI patients could be discharged eventually 10.6 days earlier and 3,909 € could be saved. Single-dose intravenous Dalbavancin is thus an option for patients with ABSSSI and JBPI who are eligible for discharge.


  • Open Access

    Reimbursement in Endoscopy: How Can New Procedures Be Implemented?

    by Michael-Holger Wilke, Markus Rathmayer

    Background: New procedures in endoscopy take time to be incorporated in the German diagnosis-related groups (DRG) system. Depending on the extent of innovation and the costs, several pathways are possible. Methods: This article provides an overview of possible pathways to implement new procedures in the German DRG payment system. Additionally, we compare the results of 2 surveys on the system of New Diagnostic and Treatment Methods (Neue Untersuchungs- und Behandlungsmethoden; NUB). Furthermore, the pathways of 2 innovations in endoscopy are described in detail and compared with the possibilities within the legal framework. Results: The different pathways like NUB applications or DRG change requests and the underlying legal framework are described in detail. The results of a survey from 2007 on the daily practice of NUB funding in Germany show that the extent of innovations which receive a positive assessment (status 1) is 46% compared to 43.7% in a survey from 2007, and that 77% of the status 1 procedures (and drugs) can be negotiated into a payment - compared to 53% in the older survey. Conclusion: Medical scientific societies should be involved in this process from the beginning. Besides the importance for the hospital application process (81.3% of all medical controllers want to have society support), the regulatory bodies (e.g. DIMDI, InEK, G-BA) also appreciate scientific statements. Two examples show the pathways in detail. For radiofrequency ablation of Barrett's esophagus, the pathway of continuous change requests was chosen, while the endoluminal conduit for the treatment of type 2 diabetes was established as NUB payment.